Podcast CME Course Information

Exam: Exam 159

Issue: December 4, 2012

Learning Objectives

Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant

Upon completion of this podcast, the participant will be familiar with the neurobiology of orexin and sleep.

Recommended Audience

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

Core Competencies

• Medical Knowledge

Disclosures

Program Accreditation and Development Subcommittee (PADS) is responsible for reviewing and evaluating all CME programs. PADS members: Pradeep K. Sahota MD, FAAN, has nothing to disclose, Allison Brashear MD, FAAN, has received personal compensation for activities with Allergan, Merz, Ipsen and Osmotica as a consultant, has received personal compensation in an editorial capacity for Wemove, has received research support from Allergan, Merz, and Ipsen, J. Clay Goodman MD, FAAN, has nothing to disclose, Steven L. Lewis MD, FAAN, has received personal compensation in an editorial capacity for the journal Neurology, Barbara F. Westmoreland MD, FAAN, has nothing to disclose, Susan Rodmyre, has nothing to disclose.

Robert A. Gross, MD, PhD, FAAN has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center’s Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past five years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers’ bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers’ bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology.

Dr. Ted Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (35% effort); and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals. AAN staff members editing the test (P Baskin, L Kleffman) have no disclosures. The CME Journal Editors who have reviewed the exam are Steven Lewis, MD, who receives a stipend in his editorial capacity for Neurology and as an Associate Editor for Continuum: Lifelong Learning in Neurology; has received royalties for the books 'Field Guide to the Neurologic Examination' and 'Neurology for the Non-Neurologist;' and anticipates receiving royalties for the book 'Neurologic Disorders due to Systemic Disease;' and James WM Owens Jr. MD PhD, who receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology.

Dr. Roth serves on the scientific advisory boards for Merck, Jazz and Transcept; serves as an editorial board member for Sleep and Sleep Medicine; receives research support from Transcept Pharmaceuticals, Impax Pharmaceuticals, Linguflex LLC and APnes, serves on the speakers’ bureau of Purdue Pharma L.P. and is a consultant for Abbott Laboratories, Accadia, Acogolix Inc., Acorda, Actelion Pharmaceuticals Ltd, Addrenex Pharmaceuticals, Inc, Alchemers, Alza Corporation, Ancel, Arena, AstraZeneca, Aventis, AVER, Bayer Schering Pharma, BMS, BTG, Cephalon, Inc., Cypress, Dove, Eisai Inc., Elan Corporation, Eli Lilly and Company, Evotec, Forest Laboratories, Inc., GlaxoSmithKline, Hypnion Inc, Impax Pharmaceuticals, Intec, Intra-Cellular Therapies, Jazz, Johnson & Johnson, King Pharmaceuticals, Lundbeck, Inc., McNeil, MediciNova, Merck, Neurim Pharmaceuticals Ltd, Neurocrine, Neurogen, Novartis, Orexo, Organon Pharmaceuticals, Otsuka Pharmaceuticals, Inc., Prestwick, Proctor & Gamble Pharmaceuticals, Pfizer Inc, Purdue Pharma L.P., Resteva, Roche, Sanofi-aventis, Schoering-Plough Corp., Sepracor Inc., Servier Laboratories, Shire plc, Somaxon Pharmaceuticals, Syrex, Takeda Pharmaceutical Company Limited, TransOral, Yanda, VivoMetrics Inc, Wyeth, Yamanuchi Pharmaceutical, and XenoPort. Dr. Herring is Executive Director, Clinical Neuroscience at Merck; receives research support as an employee at Merck and holds stock options with Merck. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Weathers receives honoraria as an AAN speaker.

The other participants had nothing to disclose.

CME Expiration

CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.

Accreditation

The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit™

The American Academy of Neurology designates that participants will receive 0.5 AMA PRA Category 1 CME credits™ by answering the multiple-choice questions in the online Podcast quiz.

Copyright

The American Academy of Neurology holds copyright for all materials in this exam.

Confidentiality

Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.

Hardware and Software Requirements

A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.

Start this exam